Introduction: The 2009-H1N1 influenza pandemic has prompted new global efforts to
develop new drugs and drug design techniques to combat influenza viruses. While there …

Seasonal and pandemic influenza have caused high morbidity and mortality worldwide.
Recent emergence of influenza A H5N1 and H1N1 strains has heightened concern …

Influenza is a seasonal and serious health threat, and the recent outbreak of H7N9 following
the pandemic spread of H1N1 in 2009 has served to emphasize the importance of anti …

Design of novel H5N1 inhibitors is currently a research topic of vital importance owing to
both a recent pandemic threat by the worldwide spread of H5N1 avian influenza and the …

Introduction: The emergence of the highly pathogenic avian influenza (HPAI) H5N1 virus
and the recent global circulation of H1N1 swine-origin influenza virus in 2009 have …

Influenza A is an acute respiratory infectious disease caused by the influenza A virus, which
seriously threatens global human health and causes substantial economic losses every …

Highlights•The existing influenza drugs suffer from variable efficacy and risk of
resistance.•Several new inhibitors of diverse viral targets are in clinical trials.•Broadly …

Influenza viruses have acquired resistance to approved neuraminidase-targeting drugs,
increasing the need for new drug targets for the development of novel anti-influenza drugs …

Pandemic (H1N1) influenza poses an imminent threat. Nations have stockpiled inhibitors of
the influenza protein neuraminidase in hopes of protecting their citizens, but drug-resistant …

It will take only a few years, even with constant surveillance, before the avian influenza
subtype H5N1 virus has spread around the world. The main agents that can use to fight the …